"The product used in treatment of chronic pain or cancer related pain will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St Louis," Cadila Healthcare, a part of Zydus group, said in a filing to the BSE.
A subsidiary of Zydus Pharmaceuticals Inc, Nesher, has considerable expertise in niche therapies with development or products barrier, such as controlled release medications, it added.
Shares in Cadila Healthcare, on Wednesday, ended 1.6 per cent higher at Rs 1825.45 apiece on the BSE.
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.